Second-line treatment of NSCLC adenocarcinoma patients not harboring an oncogene driver mutation anno 2017-2018: A Belgian perspective
(2018) Belgian Journal of Medical Oncology — Vol. 12, n° 2, p. 61-66 (2018)
Files
BaugnéePEBJMO2018.pdf
Open Access - Adobe PDF
- 256.18 KB
Details
- Authors
- et. al.
- Abstract
- The treatment landscape for patients with advanced non-small cell lung cancer, who do not harbour an oncogenic driver abnormality, has changed dramatically over the last years. Second-generation antiangiogenic agents, such as nintedanib and ramucirumab, and particularly PD-1/PD-L1 inhibitors, such as nivolumab, pembrolizumab and atezolizumab have shown to prolong survival in pretreated non-small cell lung cancer patients. Immune checkpoint inhibition in the treatment of advanced non-small cell lung cancer comes with the promise of durable responses in responding patients. Nevertheless, one must appreciate that the average response rate seen with these PD-1/PD-L1 targeting agents is only about 20%. While PD-L1 testing may be used as an enrichment biomarker, a substantial proportion of patients still do not benefit from these agents. They could benefit from alternative therapeutic options, including novel anti-angiogenic agents. In this paper, a treatment algorithm is proposed that aims to optimise the second-line treatment choice for patients with lung adenocarcinoma, based on the available clinical data.
- Affiliations
Citations
Baugnée, P., Bosquée, L., Compère, C., D’Haene, N., Desmedts, I., Galdermans, D., Germonprée, P., Gustin, M., Ninane, V., Ocak, S., & et al. (2018). Second-line treatment of NSCLC adenocarcinoma patients not harboring an oncogene driver mutation anno 2017-2018: A Belgian perspective. Belgian Journal of Medical Oncology, 12(2), 61-66. https://hdl.handle.net/2078.5/167422 (Original work published 2018)